Sort   by:  
 Page size 
UnknownPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Not available
S-EPMC11702892 | biostudies-literature
Unknown18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome.
Not available
S-EPMC6954460 | biostudies-literature
Unknown18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients.
Not available
S-EPMC9730929 | biostudies-literature
UnknownDevelopment of a Questionnaire for the Search for Occupational Causes in Patients with Non-Hodgkin Lymphoma: The RHELYPRO Study.
Not available
S-EPMC8068898 | biostudies-literature
UnknownRationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
Not available
S-EPMC4938339 | biostudies-literature
UnknownTaking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.
Not available
S-EPMC10372876 | biostudies-literature
UnknownControversies in the Treatment of Peripheral T-cell Lymphoma.
Not available
S-EPMC7469987 | biostudies-literature
UnknownP1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Not available
S-EPMC9430742 | biostudies-literature
UnknownPhase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
Not available
S-EPMC11414093 | biostudies-literature
UnknownCytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.
Not available
S-EPMC4671111 | biostudies-literature
Sort   by:  
 Page size